PremiumThe FlyeFFECTOR Therapeutics trading resumes eFfector sees no ‘obvious’ path forward for tomivosertib development in NSCLC eFFECTOR Therapeutics trading halted, news pending PremiumCompany AnnouncementseFFECTOR Therapeutics Regains Nasdaq Compliance Status eFFECTOR Therapeutics Secures $15M in Direct Offering eFfector to sell 1.49M shares at $10.075 in registered direct offering PremiumThe FlyeFfector Therapeutics board approves 1-for-25 reverse stock split eFfector announces interim data from Phase 2 expansion cohorts of zotatifin eFFECTOR Therapeutics receives Fast Track Designation for zotatifin combination